- ISIN
- IE00BYXG2H39
- Issuer
- iShares
- Inception Date
- Oct 19, 2017
- Region
- North America (United States)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- NASDAQ Biotechnology NET Index
- Domicile
- Ireland
- Distribution Policy
- Accumulating
- Asset Class
- Equity
- Asset Class Size
- Mid-Cap
- Asset Class Style
- Blend
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BTEC.L Performance Chart
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) is up 15.2% since the beginning of the year. BTEC.L is currently trading at $10 per share. Investors who bought $1,000 worth of BTEC.L shares 5 years ago would now be looking at an investment worth $1,330.
Loading charts...
Returns By Period
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) has returned 15.22% so far this year and 50.31% over the past 12 months.
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
- 1D
- 0.68%
- 1M
- 9.55%
- 6M
- 13.18%
- YTD
- 15.22%
- 1Y
- 50.31%
- 3Y*
- 16.99%
- 5Y*
- 5.87%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.38%
- 1M
- 0.24%
- 6M
- 9.32%
- YTD
- 10.62%
- 1Y
- 21.28%
- 3Y*
- 18.90%
- 5Y*
- 11.84%
- 10Y*
- 13.36%
BTEC.L Monthly Returns History
Based on dividend-adjusted daily data since Oct 19, 2017, BTEC.L's average daily return is +0.04%, while the average monthly return is +0.77%. At this rate, an investment would double in approximately 7.5 years.
Historically, 53% of months were positive and 47% were negative. The best month was Apr 2020 with a return of +15.3%, while the worst month was Oct 2018 at -15.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, BTEC.L closed higher 50% of trading days. The best single day was Nov 4, 2020 with a return of +7.2%, while the worst single day was Mar 12, 2020 at -8.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.65% | 2.93% | -4.44% | 1.79% | 1.99% | 10.33% | -0.36% | 15.22% | |||||
| 2025 | 6.40% | -2.56% | -5.25% | -0.16% | -3.26% | 4.05% | 6.81% | 3.03% | 3.68% | 10.37% | 8.75% | -1.66% | 32.96% |
| 2024 | 0.16% | 0.78% | -0.16% | -5.91% | 5.29% | 3.30% | 7.60% | -0.56% | -1.70% | -2.17% | -0.44% | -7.27% | -2.04% |
| 2023 | 4.08% | -6.18% | 0.81% | 1.71% | -3.26% | 0.90% | 1.19% | 0.67% | -4.18% | -7.50% | 5.85% | 13.73% | 6.22% |
| 2022 | -13.86% | -2.30% | 4.77% | -8.27% | -3.35% | 0.84% | 3.67% | -0.27% | -0.45% | 7.16% | 2.80% | -1.46% | -11.92% |
| 2021 | 6.28% | -3.69% | -4.38% | 4.16% | -2.02% | 8.13% | -0.32% | 3.00% | -3.09% | -3.14% | -4.75% | 0.39% | -0.49% |
Benchmark Metrics
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) has an annualized alpha of 4.33%, beta of 0.39, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since October 19, 2017.
- This ETF participated in 85.51% of S&P 500 Index downside but only 68.86% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.39 may look defensive, but with R2 of 0.11 this ETF is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this ETF's risk.
- R2 of 0.11 means this ETF moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4.33%
- Beta
- 0.39
- R²
- 0.11
- Upside Capture
- 68.86%
- Downside Capture
- 85.51%
Expense Ratio
BTEC.L has an expense ratio of 0.35%, placing it in the medium range.
Return for Risk
Risk / Return Rank
BTEC.L ranks 90 for risk / return — in the top 90% of ETFs on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BTEC.L | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.71 | ||
| Sortino ratioReturn per unit of downside risk | +1.01 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.31 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 6.22 | 2.35 | +3.87 |
| Martin ratioReturn relative to average drawdown | 19.15 | 10.19 | +8.96 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the iShares Nasdaq US Biotechnology UCITS ETF USD (Acc). A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) was 38.42%, occurring on Jun 16, 2022. Recovery took 860 trading sessions.
The current iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) drawdown is 3.87%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-38.42%Jun 2022 | 9mo 12d | 3y 4mo | 4y 2moSep 2021 - Nov 2025 | Bear market2022 |
-26.43%Dec 2018 | 2mo 23d | 1y | 1y 2moOct 2018 - Dec 2019 | Rate-hike selloffLate 2018 |
-21.18%Mar 2020 | 1mo 2d | 28d | 2moFeb 2020 - Apr 2020 | COVID crash2020 |
-17.02%Mar 2021 | 23d | 5mo 7d | 6moFeb 2021 - Aug 2021 | — |
-13.71%Apr 2018 | 2mo 6d | 3mo 8d | 5mo 14dJan 2018 - Jul 2018 | — |
Drawdown Indicators
| BTEC.L | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.42% | -56.78% | +18.36% |
Max Drawdown (1Y)Largest decline over 1 year | -7.94% | -9.10% | +1.16% |
Max Drawdown (3Y)Largest decline over 3 years | -26.74% | -18.90% | -7.84% |
Max Drawdown (5Y)Largest decline over 5 years | -38.42% | -25.43% | -12.99% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -3.87% | -0.49% | -3.38% |
Average DrawdownAverage peak-to-trough decline | -13.22% | -10.70% | -2.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.58% | 2.09% | +0.49% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with BTEC.L
Add iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BTEC.L